WO2015129281A1 - Agent prophylactique et/ou thérapeutique pour troubles gastro-intestinaux fonctionnels - Google Patents

Agent prophylactique et/ou thérapeutique pour troubles gastro-intestinaux fonctionnels Download PDF

Info

Publication number
WO2015129281A1
WO2015129281A1 PCT/JP2015/001042 JP2015001042W WO2015129281A1 WO 2015129281 A1 WO2015129281 A1 WO 2015129281A1 JP 2015001042 W JP2015001042 W JP 2015001042W WO 2015129281 A1 WO2015129281 A1 WO 2015129281A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactic acid
functional gastrointestinal
gastrointestinal tract
acid bacteria
ingestion
Prior art date
Application number
PCT/JP2015/001042
Other languages
English (en)
Japanese (ja)
Inventor
古賀　泰裕
敦司 高木
俊広 大津
Original Assignee
株式会社明治
学校法人東海大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治, 学校法人東海大学 filed Critical 株式会社明治
Priority to SG11201604840TA priority Critical patent/SG11201604840TA/en
Priority to CN201580010779.8A priority patent/CN106029081A/zh
Priority to JP2016505079A priority patent/JP6781887B2/ja
Publication of WO2015129281A1 publication Critical patent/WO2015129281A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the present invention relates to an oral intake agent for preventing and / or improving functional gastrointestinal disorders such as functional dyspepsia.
  • Patent Document 1 and Patent Document 2 describe that functional gastrointestinal disorders were improved by administration of glutamic acid, 5′-nucleotide and the like (each claim 1).
  • Patent Document 3 describes a functional gastrointestinal tract preventive / ameliorating agent containing glutamic acid and arginine as active ingredients.
  • This preventive / ameliorating agent is easy to manufacture, low in cost and high in safety, especially in upper areas such as functional gastroenteropathy (FD) such as abdominal pain, stomach upset, heartburn and gastroesophageal reflux disease (GERD) It is said to be effective for digestive tract disorders (summary).
  • FD functional gastroenteropathy
  • GID gastroesophageal reflux disease
  • Patent Document 4 has a sterilizing action of Helicobacter pylori (hereinafter sometimes referred to as H. pylori).
  • H. pylori Helicobacter pylori
  • Bifidobacterium bifidum hereinafter sometimes referred to as bifidobacteria
  • bifidobacteria Bifidobacterium bifidum
  • Patent Document 5 shows that the Lactobacillus gasseri MCC 1183 strain has a sterilizing action against Helicobacter pylori.
  • Patent Document 6 describes a Lactobacillus lactic acid bacterium such as Lactobacillus acidophilus (Lactobacillus gasseri), a Streptococcus lactic acid bacterium such as Streptococcus faecalis, and a gastrointestinal function enhancer containing aloe (Claim 1). , 2, paragraph 0012), it is described that the enhancement of gastrointestinal function includes improvement of stomach sag and abdominal bloating (paragraph 0043).
  • a technique for eradicating H. pylori and improving functional gastrointestinal disorders by using a fermented milk beverage containing lactic acid bacteria such as bifidobacteria has already been known.
  • the applicant of the present invention relates to a Helicobacter pylori sterilization and / or infection prevention pharmaceutical agent containing Lactobacillus gasseri OLL2716 strain, which is a lactic acid bacterium having high sterilization ability of H. pylori as an active ingredient.
  • the pharmaceutical agent is used as an anti-gastritis agent or an anti-ulcer agent (claims 1 and 3).
  • Lactobacillus gaselli OLL2716 strain was effective as a functional gastrointestinal tract disorder preventing and / or ameliorating agent.
  • Lactobacillus gasseri OLL2716 strain is effective in preventing and / or improving functional gastrointestinal disorders.
  • Lactobacillus gasseri OLL2716 was found to be able to prevent and / or ameliorate functional gastrointestinal disorders irrespective of the eradication of Helicobacter pylori.
  • the Lactobacillus gasseri OLL2716 strain can prevent and / or ameliorate functional gastrointestinal disorders even for H. pylori-negative individuals.
  • Lactobacillus gasseri OLL2716 strain has an effect of preventing and / or improving functional gastrointestinal dysfunctions not only against H. pylori positive but also H. pylori negative.
  • improvement of functional gastrointestinal tract disorders using only lactic acid bacteria as active ingredients as described in Patent Documents 4 and 5, it is assumed that Helicobacter pylori is eradicated (decreased). There was no suggestion that an effect could be expected even in the negative.
  • the present invention has been made in view of the above circumstances, and can prevent and / or improve functional gastrointestinal disorders for both positive and negative persons with H. pylori, such as an oral ingestion agent, etc.
  • the purpose is to provide.
  • the functional gastrointestinal tract disorder preventive and / or ameliorating agent of the present invention is for Helicobacter pylori positive and negative persons and contains lactic acid bacteria as an active ingredient.
  • lactic acid bacteria and Lactobacillus lactic acid bacteria are preferably used, and Lactobacillus gasseri OLL 2716 (FERM BP-6999) is more preferably used as the Lactobacillus lactic acid bacteria.
  • the present invention is preferably used as an agent for preventing and / or improving functional gastrointestinal tract disorders for H. pylori negative persons.
  • the daily dose of the lactic acid bacteria to human beings is preferably 2 ⁇ 10 7 to 5 ⁇ 10 10 , and 10 7 or more per 1 g of the lactic acid bacteria culture.
  • the daily dose of the lactic acid bacteria culture to humans is preferably 5 to 1000 g.
  • the functional gastrointestinal tract preventive and / or ameliorating agent of the present invention has a rapid effect, and the rapid effect exhibits a functional gastrointestinal tract disorder improving effect 4 weeks after ingestion.
  • examples of functional gastrointestinal tract disorders include a feeling of stomach sag or abdominal bloating.
  • the functional gastrointestinal tract disorder preventing and / or improving agent of the present invention is provided as a functional food such as a health supplement, health functional food, or supplement.
  • an oral intake agent or the like that can prevent and / or ameliorate functional gastrointestinal tract disorders for both positive and negative persons with H. pylori.
  • VAS score the feeling of stomach sag (VAS score) by the intake of the functional gastrointestinal tract disorder prevention and / or ameliorating agent according to an embodiment of the present invention (a group in which fecal H. pylori antigen (OD value) has not decreased).
  • OD value fecal H. pylori antigen
  • VAS score abdominal fullness
  • OD value pylori antigen
  • VAS score the feeling of abdominal bloating
  • the functional gastrointestinal tract disorder preventing and / or improving agent (hereinafter sometimes referred to as FD improving agent) according to an embodiment of the present invention is for positive and negative persons of H. pylori, and uses lactic acid bacteria as an active ingredient. It is characterized by containing. According to the embodiment of the present invention, it is possible to provide an FD improving agent having a lactic acid bacterium as an active ingredient which generally has a eating habit and has few side effects. For example, according to the embodiment of the present invention, an FD improving agent can be provided even for H. pylori negative persons.
  • Lactic acid bacteria are generally used in fermented foods such as yogurt, cheese, butter, and pickles, and some have a familiar flavor and are easy to take. As long as lactic acid bacteria in the embodiment of the present invention produce lactic acid by assimilating saccharides, the genus, species and origin thereof are arbitrary. Of these, lactic acid bacteria belonging to the genus Lactobacillus, particularly Lactobacillus gasseri, are preferred, and Lactobacillus gasli OLL 2716 (FERM BP-6999) can be suitably used.
  • Functional gastrointestinal disorders in the embodiments of the present invention include no organic diseases such as peptic ulcer and cancer symptoms, gastrointestinal tract, stomach sag, abdominal bloating, nausea / vomiting, upper abdominal pain, It refers to the pathological condition followed by upper abdominal indefinite complaints such as loss of appetite or abnormal bowel movements, and is a symptom in which reproducible gastrointestinal symptoms that reduce the patient's QOL are observed even if no organic diseases of the digestive tract are observed.
  • Such functional gastrointestinal dysfunction is a disease that has been diagnosed as chronic gastritis or gastritis, and is characterized by symptoms such as abdominal pain, stomach upset, heartburn.
  • Such functional gastrointestinal tract disorders do not show organic diseases of the gastrointestinal tract.
  • the digestive tract refers to a luminal organ involved in a series of digestion from the oral cavity to the anus. Examples include the pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), and large intestine.
  • the upper digestive tract refers to the pharynx, esophagus, stomach, and duodenum.
  • the number of lactic acid bacteria as an active ingredient in the FD improving agent is preferably 2 ⁇ 10 7 to 5 ⁇ 10 10 as an effective amount (intake amount) per day for humans. 5 ⁇ 10 7 to 5 ⁇ 10 10 , more preferably 1 ⁇ 10 8 to 5 ⁇ 10 10 , more preferably 5 ⁇ 10 8 to 5 ⁇ 10 10 , more preferably 5 ⁇ 10 It is desirable to contain 8 to 2 ⁇ 10 10 so that it can be ingested.
  • the FD improving agent is incorporated so that the number of lactic acid bacteria is less than 2 ⁇ 10 7 , it is difficult to prevent and / or improve the functional gastrointestinal tract disorder in humans. This is because even if the number of bacteria is contained so as to be ingested more than 5 ⁇ 10 10 , the effect is not greatly changed.
  • the culture of lactic acid bacteria is included in the FD improving agent.
  • the effective amount (intake amount) per day may be taken for a human in one time, or may be taken in two or more times.
  • the number of lactic acid bacteria included per 1 g of the lactic acid bacteria culture may be 10 7 or more, and may be 10 7 , 10 8 , 10 9 or the like. If the number of lactic acid bacteria included per gram of the lactic acid bacteria culture is increased, the effective amount of the lactic acid bacteria culture can be reduced while including the effective number of lactic acid bacteria in the FD improving agent. By taking a smaller amount of food, it is possible to obtain the same effect of preventing and / or improving functional human digestive tract disorders.
  • the culture of lactic acid bacteria in the embodiment of the present invention can be obtained by culturing (growing) lactic acid bacteria with known medium components. Moreover, the number of lactic acid bacteria per unit weight of a culture solution can be raised by centrifuging the obtained culture solution of lactic acid bacteria.
  • the lactic acid bacterium in the embodiment of the present invention may be in a state of just being cultured (proliferated), may be mixed with a cryoprotectant or the like, may be frozen, or may be lyophilized.
  • the lactic acid bacteria in the embodiment of the present invention may be live or dead, and preferably live.
  • lactic acid bacteria can be separated from “Meiji Probio Yogurt LG21” sold by Meiji Co., Ltd.
  • the other ingestible components are not limited, but for example, dairy components are preferably used.
  • the dairy component means a composition containing milk itself or a milk component obtained by processing milk, for example, raw milk (such as milk), reduced milk (milk powder, cream, butter), fermented milk (yogurt, cheese), milk Including all ingredients including milk components such as preparations (whey, casein, lactose, whey minerals, permeates), the origin and form are not particularly limited.
  • the FD improving agent according to the embodiment of the present invention has a rapid action, and particularly has a functional gastrointestinal disorder improving effect in 4 weeks.
  • this does not restrict the continuous intake of the FD improving agent according to the embodiment of the present invention for longer than 4 weeks, and it is preferable to continuously take it for 4 weeks or more. It is more preferable to continuously take the above, more preferably to take continuously for 12 weeks or more, still more preferably to take continuously for 16 weeks or more, and even more preferably to take continuously for 20 weeks or more.
  • the FD improving agent according to the embodiment of the present invention is not particularly limited in the intake method and the intake frequency.
  • an FD improving agent is taken daily as an example, and the preferred number of lactic acid bacteria per day is shown in the above embodiment, but if not taken every day, the embodiment of the present invention is used. It does not mean that FD improvement effects are not recognized. As long as the effect is recognized, the intake frequency is changed to, for example, once every two days, once every three days, once every four days, once every five days, once every seven days (one week), and every ten days. Times, once a month, etc.
  • the FD improving agent according to the embodiment of the present invention can be composed of a unit packaging form per serving, and can also be a form including the number of effective lactic acid bacteria per unit packaging.
  • lactic acid bacteria as an active ingredient per unit package so that 2 ⁇ 10 7 to 5 ⁇ 10 10 can be ingested, and 5 ⁇ 10 7 to 5 ⁇ 10 10 ingested. More preferably, it is contained so that it is ingested at 1 ⁇ 10 8 to 5 ⁇ 10 10 pieces, and more preferably, it is contained so that it is ingested at 5 ⁇ 10 8 to 5 ⁇ 10 10 pieces.
  • the lactic acid bacteria culture as an active ingredient is contained per unit package so as to be ingested at 5 to 1000 g. More preferably, it is contained so that it can be ingested at ⁇ 1000 g, more preferably, it is contained so that it can be ingested at 50-500 g, and more preferably, it is contained so that it can be ingested at 70-300 g. More preferably, it is contained so as to be ingested at 250 g, and particularly preferably contained so that it is ingested at 80 to 200 g.
  • the FD improving agent according to the embodiment of the present invention is packaged per unit package
  • a known package can be used.
  • paper, plastic, glass, nylon, stainless steel, aluminum, iron, copper, silver, bamboo, etc. are not particularly limited.
  • the lactic acid bacteria are facultative anaerobic bacteria, it is preferable that the lactic acid bacteria are not exposed to air or oxygen.
  • the method of ingesting the FD improving agent is not particularly limited, and all of the known ingestion forms such as oral, tube, enteral, vascular injection, coating, suppository, etc. can be applied. Ingestion can be suitably used.
  • the temperature of the FD improving agent when ingesting the FD improving agent is preferably ⁇ 30 to 50 ° C., more preferably ⁇ 20 to 45 ° C., and 0 to 45 ° C. More preferably, it is 0 to 30 ° C, more preferably 0 to 20 ° C, and particularly preferably 0 to 10 ° C.
  • the FD improving agent may contain other ingestible components, various additives, raw materials for pharmaceuticals, and the like as components other than lactic acid bacteria.
  • Example 1 A solid FD improving agent containing Lactobacillus gasseri OLL 2716 (FERM BP-6999) as an active ingredient was prepared by the following method. Using raw material milk, skim milk powder, and water, adjust the milk fat content to 3.0% by weight and non-fat milk solid content to 9.2% by weight, and homogenize the resulting mixture by the usual method. Then, sterilization and cooling treatment were performed. Then, inoculated with Lactobacillus bulgaricus, Streptococcus thermophilus and Lactobacillus gasseri OLL 2716 (FERM BP-6999) isolated from Meiji Co., Ltd. "Meiji Probio Yogurt LG21" The obtained culture was designated as Example 1 (FD improving agent).
  • FD improving agent Lactobacillus gasseri OLL 2716
  • this FD improving agent takes lactic acid bacteria containing an active ingredient as it is for convenience.
  • the number of Lactobacillus gasseri OLL 2716 (FERM BP-6999) lactic acid bacteria per gram was approximately 10 7 .
  • Example 1 A solid placebo (placebo) that did not contain Lactobacillus gasseri OLL 2716 (FERM BP-6999) was prepared by the following method. Using raw material milk, skim milk powder, and water, adjust the milk fat content to 3.0% by weight and non-fat milk solid content to 9.2% by weight, and homogenize the resulting mixture by the usual method. Then, sterilization and cooling treatment were performed. Thereafter, Lactobacillus bulgaricus and Streptococcus thermophilus isolated from Meiji Co., Ltd. “Meiji Probio Yogurt LG21” were inoculated and cultured in the usual manner, and the resulting culture was used as Comparative Example 1 (placebo).
  • this placebo does not contain Lactobacillus gasseri OLL 2716 (FERM BP-6999) lactic acid bacteria contained in Example 1, and Lactobacillus gasseri OLL 2716 (FERM BP-6999) per gram in the placebo.
  • the number of lactic acid bacteria is 0.
  • Test method 1 Using the FD improving agent of Example 1 and the placebo of Comparative Example 1 (hereinafter, these may be referred to as test samples), a randomized placebo-controlled double-blind intervention study was performed. Specifically, a group of subjects who randomly ingest the H. pylori-infected persons who are 30 years of age or older and who do not have an organic disease and who ingest the FD improving agent of Example 1 (hereinafter sometimes referred to as an FD improving agent group). And a group of subjects taking the placebo of Comparative Example 1 (hereinafter sometimes referred to as a placebo group). During the test period, all the subjects and the tester were controlled so that the group to which each subject belonged was not known. The subjects in the FD improving agent group received FD improving agents, and the subjects in the placebo group received placebo 90 g daily for 12 weeks.
  • VAS visual analog scale
  • each subject's fecal H. pylori antigen (OD value) was confirmed by a conventional method. Confirmation of fecal H. pylori antigens was performed before and 12 weeks after ingestion of the test sample.
  • the feeling of stomach sag is greatly reduced in 4 weeks after ingestion. That is, it was revealed that the FD improving agent of Example 1 has an effect of improving functional gastrointestinal tract disorders 4 weeks after ingestion. Since it takes about 12 weeks until the effect of improving the functional gastrointestinal tract is obtained by the oral ingestion agent or the like, the functional gastrointestinal tract disorder preventing and / or improving agent according to the embodiment of the present invention is excellent in rapid action. It was found to have sex.
  • Example 1 reduced the feeling of abdominal fullness not only in subjects whose H. pylori decreased, but also in subjects whose H. pylori did not decrease. That is, it has been clarified that the effect of improving the feeling of abdominal distension by the functional gastrointestinal tract disorder preventing and / or improving agent according to the embodiment of the present invention does not depend on the sterilization of H. pylori.
  • Test method 2 Using the FD improving agent of Example 1, a test using an F-scale questionnaire for gastroesophageal reflux disease (GERD) (Frequency Scale for the Symptoms of GERD, hereinafter sometimes referred to as FSSG) was performed. Specifically, 24 patients taking a gastric acid secretion inhibitor (23 H. pylori-negative and 1 H. pylori-positive) were taken as a group of subjects taking the FD improving agent of Example 1. And the test subject of this group was made to ingest 118g of FD improvement agents per day continuously for 12 weeks.
  • GSD gastroesophageal reflux disease
  • gastrointestinal dysfunction subject symptoms: acid reflux related symptoms (Reflux), dyskinesia (dysmotility)
  • F-scale questionnaire for gastroesophageal reflux disease This FSSG evaluation was performed by summing up the scores of subjects for each predetermined item, assuming that the case where the symptom was felt was 4 and the case where the symptom was not felt was 0.
  • FSSG acid reflux-related symptoms are as follows: Question 1 (Do you suffer from heartburn?), Question 2 (Do you rub your chest unexpectedly with your palm?), Question 3 (After eating, heartburn may occur) ), Question 4 (Is there a sense of discomfort in the throat (burning, etc.)?), Question 5 (Can I use it if I swallow things up), Question 6 (Bitter water (stomach acid) may rise) Is there any ??) and Question 7 (Do you get heartburn when you lean forward?)
  • the evaluation of FSSG dyskinetic symptoms was as follows: Question 8 (Do you sometimes feel hungry?), Question 9 (Do you have a heavy stomach after eating?), Question 10 (Eating) After that, I added up the total of Question 11 (Do you feel full during the meal?) And Question 12 (Do you often get gop?).
  • the functional gastrointestinal tract disorder preventing and / or ameliorating agent according to the embodiment of the present invention has an effect of improving the functional gastrointestinal tract disorder, particularly in the upper abdomen such as the esophagus. It turned out that it did not depend on the secretion suppression of bacteria and gastric acid.
  • the present invention can be suitably used to prevent or improve functional gastrointestinal tract disorders by a method without side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

　La présente invention concerne un agent oral ou équivalents capable de prévenir et/ou d'améliorer les troubles gastro-intestinaux fonctionnels chez les individus positifs et négatifs pour Helicobacter pylori. La présente invention concerne par conséquent un agent prophylactique et/ou thérapeutique pour troubles gastro-intestinaux fonctionnels, l'agent contenant des lactobacilles en tant qu'ingrédient actif, à utiliser chez des individus positifs et négatifs pour Helicobacter pylori. Les lactobacilles utilisés sont de préférence les lactobacilles du genre Lactobacillus, de manière davantage préférée Lactobacillus gasseri OLL 2716 (FERM BP -6999).
PCT/JP2015/001042 2014-02-28 2015-02-27 Agent prophylactique et/ou thérapeutique pour troubles gastro-intestinaux fonctionnels WO2015129281A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SG11201604840TA SG11201604840TA (en) 2014-02-28 2015-02-27 Prophylactic and/or therapeutic agent for functional gastrointestinal disorders
CN201580010779.8A CN106029081A (zh) 2014-02-28 2015-02-27 功能性消化道障碍预防和/或改善剂
JP2016505079A JP6781887B2 (ja) 2014-02-28 2015-02-27 機能性消化管障害予防及び／又は改善剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014038586 2014-02-28
JP2014-038586 2014-02-28

Publications (1)

Publication Number Publication Date
WO2015129281A1 true WO2015129281A1 (fr) 2015-09-03

Family

ID=54008612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/001042 WO2015129281A1 (fr) 2014-02-28 2015-02-27 Agent prophylactique et/ou thérapeutique pour troubles gastro-intestinaux fonctionnels

Country Status (5)

Country Link
JP (2) JP6781887B2 (fr)
CN (1) CN106029081A (fr)
HK (1) HK1225637A1 (fr)
SG (1) SG11201604840TA (fr)
WO (1) WO2015129281A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017221799A1 (fr) * 2016-06-20 2017-12-28 株式会社明治 Agent améliorant la flore gastro-intestinale supérieure.
WO2018012578A1 (fr) * 2016-07-14 2018-01-18 株式会社明治 Promoteur de sécrétion de ghréline
WO2018124003A1 (fr) * 2016-12-27 2018-07-05 株式会社明治 Procédé de détection d'un trouble gastro-intestinal fonctionnel par mesure de l'occupation de la flore gastrique, et agent améliorant la flore gastrique
JP2019048849A (ja) * 2018-11-14 2019-03-28 株式会社明治 グレリン分泌促進剤
CN114525222A (zh) * 2022-03-02 2022-05-24 山东拜因诺生物科技有限公司 一种抑幽益生菌

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190298783A1 (en) 2018-03-28 2019-10-03 Morinaga Milk Industry Co., Ltd. Composition for relieving stress, pharmaceutical composition and food and drink composition and method for relieving stress using the composition for relieving stress

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001002578A (ja) * 1999-06-24 2001-01-09 Yasuhiro Koga Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品
WO2007010977A1 (fr) * 2005-07-21 2007-01-25 Kabushiki Kaisha Yakult Honsha Nouvelle bacterie appartenant au genre bifidobacterium et utilisation de celle-ci
JP2011501664A (ja) * 2007-10-11 2011-01-13 ダニスコ・エー・エス 消化器疾患に関連する症状の緩和に使用されるプロバイオティクス
JP2011200211A (ja) * 2010-03-26 2011-10-13 Morinaga Milk Ind Co Ltd 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料
JP2012126700A (ja) * 2010-12-17 2012-07-05 Biofuerumin Seiyaku Kk 胃腸機能亢進剤
JP2012144506A (ja) * 2011-01-07 2012-08-02 Snowden Co Ltd 胃酸及びガストリンの産生を抑制する乳酸菌
JP2013517784A (ja) * 2010-01-28 2013-05-20 アベ−バイオティックス・ソシエダッド・アノニマ 腸炎症の処置における使用のためのプロバイオティクス組成物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001002578A (ja) * 1999-06-24 2001-01-09 Yasuhiro Koga Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品
WO2007010977A1 (fr) * 2005-07-21 2007-01-25 Kabushiki Kaisha Yakult Honsha Nouvelle bacterie appartenant au genre bifidobacterium et utilisation de celle-ci
JP2011501664A (ja) * 2007-10-11 2011-01-13 ダニスコ・エー・エス 消化器疾患に関連する症状の緩和に使用されるプロバイオティクス
JP2013517784A (ja) * 2010-01-28 2013-05-20 アベ−バイオティックス・ソシエダッド・アノニマ 腸炎症の処置における使用のためのプロバイオティクス組成物
JP2011200211A (ja) * 2010-03-26 2011-10-13 Morinaga Milk Ind Co Ltd 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料
JP2012126700A (ja) * 2010-12-17 2012-07-05 Biofuerumin Seiyaku Kk 胃腸機能亢進剤
JP2012144506A (ja) * 2011-01-07 2012-08-02 Snowden Co Ltd 胃酸及びガストリンの産生を抑制する乳酸菌

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKIRA TAMURA ET AL.: "The suppression of Helicobacter pylori infection by probiotics", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 207, no. 10, 2003, pages 845 - 849 *
CAMILLERI, M. ET AL.: "Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome", GASTROENTEROLOGY CLINICS OF NORTH AMERICA, vol. 39, no. 3, 2010, pages 481 - 493 *
IGARASHI, M. ET AL.: "Correlation between the Serum Pepsinogen I Level and the Symptom Degree in Proton Pump Inhibitor-Users Administered with a Probiotic", PHARMACEUTICALS, vol. 7, no. 7, June 2014 (2014-06-01), pages 754 - 764 *
KENTARO NOBUTANI ET AL.: "Lactobacillus gasseri CP2305-Kabu no Toyo ni yoru IBS Shojo no Kaizen to Masshoketsu Hakkekkyu no Idenshi Hatsugen no Henka", JAPANESE JOURNAL OF LACTIC ACID BACTERIA, vol. 24, no. 2, 2013, pages 142 *
TAKAGI, A. ET AL.: "Effect of L. Gasseri on dyspeptic symptoms in subjects with H. Pylori infection", GASTROENTEROLOGY, vol. 144, no. 5, 2013, pages S679, XP055221774, ISSN: 0016-5085 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017221799A1 (fr) * 2016-06-20 2017-12-28 株式会社明治 Agent améliorant la flore gastro-intestinale supérieure.
CN109310718A (zh) * 2016-06-20 2019-02-05 株式会社明治 上消化道内菌群改善剂
JPWO2017221799A1 (ja) * 2016-06-20 2019-04-11 株式会社明治 上部消化管内菌叢改善剤
CN109310718B (zh) * 2016-06-20 2022-06-17 株式会社明治 上消化道内菌群改善剂
JP7101354B2 (ja) 2016-06-20 2022-07-15 株式会社明治 上部消化管内菌叢改善剤
WO2018012578A1 (fr) * 2016-07-14 2018-01-18 株式会社明治 Promoteur de sécrétion de ghréline
JP2018008901A (ja) * 2016-07-14 2018-01-18 株式会社明治 グレリン分泌促進剤
CN109715180A (zh) * 2016-07-14 2019-05-03 株式会社明治 饥饿素分泌促进剂
CN115918726A (zh) * 2016-07-14 2023-04-07 株式会社明治 饥饿素分泌促进剂
WO2018124003A1 (fr) * 2016-12-27 2018-07-05 株式会社明治 Procédé de détection d'un trouble gastro-intestinal fonctionnel par mesure de l'occupation de la flore gastrique, et agent améliorant la flore gastrique
JP2019048849A (ja) * 2018-11-14 2019-03-28 株式会社明治 グレリン分泌促進剤
CN114525222A (zh) * 2022-03-02 2022-05-24 山东拜因诺生物科技有限公司 一种抑幽益生菌

Also Published As

Publication number Publication date
HK1225637A1 (zh) 2017-09-15
JPWO2015129281A1 (ja) 2017-03-30
JP2018184481A (ja) 2018-11-22
JP6781887B2 (ja) 2020-11-11
SG11201604840TA (en) 2016-09-29
CN106029081A (zh) 2016-10-12

Similar Documents

Publication Publication Date Title
JP2018184481A (ja) 機能性消化管障害予防及び／又は改善剤
RU2332224C1 (ru) ПРИМЕНЕНИЕ ТЕРАПЕВТИЧЕСКИ ЭФФЕКТИВНОГО КОЛИЧЕСТВА Bb-12 И LGG ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА ДЛЯ ПРЕДОТВРАЩЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ ИНФЕКЦИЙ И ОСТРОГО СРЕДНЕГО ОТИТА У МЛАДЕНЦЕВ
JP5832297B2 (ja) プロバイオティクスおよびプレバイオティクス構成要素ならびに無機塩をラクトフェリンとともに含む組成物
US20100166721A1 (en) Probotic compositions and uses thereof
US20110165127A1 (en) Dairy-derived probiotic compositions and uses thereof
BR112013031659B1 (pt) Uso de uma composição
JP7280069B2 (ja) 機能性消化管障害予防又は改善用組成物、並びに、該機能性消化管障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物
TW200815023A (en) Prevention and treatment of otitis media
CA2702293C (fr) Probiotiques pour une utilisation dans le soulagement de symptomes associes a des troubles gastro-intestinaux
Onyenweaku et al. Research Article Health Benefits of Probiotics
JP5816273B2 (ja) 経上皮抵抗の改善に用いるためのプロバイオティクス株
WO2015087919A1 (fr) Agent inducteur de peptide antibactérien
TWI745454B (zh) 抑制腸道內乳桿菌屬乳酸菌減少用之組成物
JP6002582B2 (ja) ガストリン産生抑制剤およびそれを含有する食品組成物
JP7101354B2 (ja) 上部消化管内菌叢改善剤
Bastani et al. Health benefits of probiotic consumption
WO2018124003A1 (fr) Procédé de détection d'un trouble gastro-intestinal fonctionnel par mesure de l'occupation de la flore gastrique, et agent améliorant la flore gastrique
PAONGPHAN et al. Characterization of probiotic lactic acid bacteria producing bile-salt hydrolase for development of fermented milk product
Betta et al. Intestinal Microbial Flora–Effect of Probiotics in Newborns
Altomare et al. The intestinal ecosystem and probiotics
Sanders et al. Use of probiotic yogurts in health and disease
CN118475359A (zh) 用于预防继发感染症或用于降低继发感染症发生风险的组合物
JP2018030798A (ja) 非ステロイド系鎮痛薬起因性小腸傷害予防及び／又は改善剤
JP2007091704A (ja) ＩｇＥ産生抑制剤、ＩｇＥ産生抑制用飲食品、抗アレルギー剤および抗アレルギー用飲食品
BG2847U1 (bg) Ацидофилно мляко

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15754957

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016505079

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15754957

Country of ref document: EP

Kind code of ref document: A1